| Hazard Information | Back Directory | [Uses]
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3]. | [in vivo]
Lorigerlimab (75 mg/kg, i.v.) shows CTLA-4 blockade in in cynomolgus monkeys[2].
Lorigerlimab (10-100 mg/kg, i.v., 4 weeks) is well tolerated in cynomolgus monkeys, and shows a half-life about 7 days[2].
| Animal Model: | Cynomolgus monkeys [4] | | Dosage: | 75 mg/kg | | Administration: | i.v. | | Result: | Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen. |
| [References]
[1] Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155.
[2] Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. DOI:10.1016/j.xcrm.2020.100163
[3] Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726. DOI:10.3389/fonc.2021.670726 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|